{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:34:39Z","timestamp":1790066079216,"version":"4.0.1"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["jsatjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Use and Addiction Treatment"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.josat.2023.209086","type":"journal-article","created":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T06:28:00Z","timestamp":1685600880000},"page":"209086","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review"],"prefix":"10.1016","volume":"152","author":[{"given":"Victoria","family":"Panwala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Joudrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paxton","family":"Bach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Amram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.josat.2023.209086_bb0005","author":"(BCCSU), B. C. C. o. S. U"},{"key":"10.1016\/j.josat.2023.209086_bb0010","series-title":"Federal regulation of methadone treatment","article-title":"4 Methadone diversion control","year":"1995"},{"key":"10.1016\/j.josat.2023.209086_bb0015","author":"Adams"},{"key":"10.1016\/j.josat.2023.209086_bb0020","author":"Administration, S. A. a. M. H. S"},{"key":"10.1016\/j.josat.2023.209086_bb0025","author":"Administration, S. A. a. M. H. S"},{"key":"10.1016\/j.josat.2023.209086_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108727","article-title":"Access to medication-assisted treatment in the United States: Comparison of travel time to opioid treatment programs and office-based buprenorphine treatment","volume":"224","author":"Amiri","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.josat.2023.209086_bb0035","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.jval.2020.08.2098","article-title":"Disparities in access to opioid treatment programs and office-based buprenorphine treatment across the rural-urban and area deprivation continua: A US nationwide small area analysis","volume":"24","author":"Amiri","year":"2021","journal-title":"Value in Health"},{"key":"10.1016\/j.josat.2023.209086_bb0040","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","article-title":"The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era","volume":"47","author":"Amram","year":"2021","journal-title":"American Journal of Drug and Alcohol Abuse"},{"issue":"6","key":"10.1016\/j.josat.2023.209086_bb0045","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1080\/00952990.2021.1979991","article-title":"The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era","volume":"47","author":"Amram","year":"2021","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"key":"10.1016\/j.josat.2023.209086_bb0050","article-title":"Changes in methadone take-home dosing before and after COVID-19","author":"Amram","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.josat.2023.209086_bb0055","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1377\/hlthaff.2020.02261","article-title":"Addressing racial and ethnic disparities in the use of medications for opioid use disorder","volume":"40","author":"Andraka-Christou","year":"2021","journal-title":"Health Affairs (Project Hope)"},{"issue":"1","key":"10.1016\/j.josat.2023.209086_bb0060","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13722-019-0158-0","article-title":"Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders","volume":"14","author":"Bach","year":"2019","journal-title":"Addiction Science & Clinical Practice"},{"key":"10.1016\/j.josat.2023.209086_bb0065","doi-asserted-by":"crossref","first-page":"103680","DOI":"10.1016\/j.drugpo.2022.103680","article-title":"Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions","volume":"104","author":"Bouck","year":"2022","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.josat.2023.209086_bb0070","article-title":"Plan N: The case for over-the-counter naloxone","author":"Bratberg","year":"2021","journal-title":"Health Affairs"},{"key":"10.1016\/j.josat.2023.209086_bb0075","series-title":"Bridging health equity gaps for people with disabilities and chronic conditions","year":"2022"},{"key":"10.1016\/j.josat.2023.209086_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108449","article-title":"Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19","volume":"131","author":"Brothers","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209086_bb0085","article-title":"The opioid epidemic in North America: Implications for Australia","volume":"578","author":"Brown","year":"2019","journal-title":"Trends and Issues in Crime and Criminal Justice"},{"key":"10.1016\/j.josat.2023.209086_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108832","article-title":"Adapting methadone inductions to the fentanyl era","volume":"141","author":"Buresh","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"6","key":"10.1016\/j.josat.2023.209086_bb0095","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s11606-018-4801-3","article-title":"Methadone matters: What the United States can learn from the global effort to treat opioid addiction","volume":"34","author":"Calcaterra","year":"2019","journal-title":"Journal of General Internal Medicine"},{"key":"10.1016\/j.josat.2023.209086_bb0100","series-title":"COVID-19 opioid agonist treatment guidance - August 2021 update","author":"CAMH","year":"2021"},{"key":"10.1016\/j.josat.2023.209086_bb0105","author":"CAMH"},{"issue":"3","key":"10.1016\/j.josat.2023.209086_bb0110","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/08897077.2020.1787300","article-title":"Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic","volume":"41","author":"Cochran","year":"2020","journal-title":"Substance Abuse"},{"key":"10.1016\/j.josat.2023.209086_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2021.103573","article-title":"Evaluating how has care been affected by the Ontario COVID-19 Opioid Agonist Treatment Guidance: Patients\u2019 and prescribers\u2019 experiences with changes in unsupervised dosing","volume":"102","author":"Corace","year":"2022","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.josat.2023.209086_bb0120","series-title":"COVID-19 opioid agonist treatment guidance","year":"2021"},{"key":"10.1016\/j.josat.2023.209086_bb0125","author":"Dorfman"},{"key":"10.1016\/j.josat.2023.209086_bb0130","author":"Doyle"},{"key":"10.1016\/j.josat.2023.209086_bb0135","doi-asserted-by":"crossref","DOI":"10.1111\/dar.13456","article-title":"Health service utilisation and access for people who inject drugs during COVID-19","author":"Efunnuga","year":"2022","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.josat.2023.209086_bb0140","series-title":"Federal guidelines for opioid treatment programs","year":"2015"},{"key":"10.1016\/j.josat.2023.209086_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108276","article-title":"Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19","volume":"123","author":"Figgatt","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2023.209086_bb0150","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12954-021-00535-y","article-title":"\u201cIt\u2019s like \u2018liquid handcuffs\u2019\u201d: The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients\u2019 lives","volume":"18","author":"Frank","year":"2021","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.josat.2023.209086_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2022.109459","article-title":"Impact of the COVID-19 pandemic on the prevalence of opioid agonist therapy discontinuation in Ontario, Canada: A population-based time series analysis","volume":"236","author":"Garg","year":"2022","journal-title":"Drug and Alcohol Dependence"},{"issue":"4","key":"10.1016\/j.josat.2023.209086_bb0160","doi-asserted-by":"crossref","first-page":"e203711","DOI":"10.1001\/jamanetworkopen.2020.3711","article-title":"Association of racial\/ethnic segregation with treatment capacity for opioid use disorder in counties in the United States","volume":"3","author":"Goedel","year":"2020","journal-title":"JAMA Network Open"},{"key":"10.1016\/j.josat.2023.209086_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109049","article-title":"The impact of COVID-19 on opioid treatment programs in the United States","volume":"228","author":"Goldsamt","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"issue":"9","key":"10.1016\/j.josat.2023.209086_bb0170","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jama.2022.1271","article-title":"Association between increased dispensing of opioid agonist therapy take-home doses and opioid overdose and treatment interruption and discontinuation","volume":"327","author":"Gomes","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2023.209086_bb0175","author":"Gowing"},{"issue":"3","key":"10.1016\/j.josat.2023.209086_bb0180","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11414-013-9341-3","article-title":"Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City","volume":"40","author":"Hansen","year":"2013","journal-title":"The Journal of Behavioral Health Services & Research"},{"key":"10.1016\/j.josat.2023.209086_bb0185","article-title":"\u201cNo home to take methadone to\u201d: Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston","author":"Harris","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209086_bb0190","author":"Hawryluk"},{"key":"10.1016\/j.josat.2023.209086_bb0195","author":"Hill"},{"key":"10.1016\/j.josat.2023.209086_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2022.108801","article-title":"Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis","author":"Hoffman","year":"2022","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209086_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2021.108288","article-title":"Clinician perspectives on methadone service delivery and the use of telemedicine during the COVID-19 pandemic: A qualitative study","volume":"124","author":"Hunter","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209086_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108008","article-title":"Characterizing variability in state-level regulations governing opioid treatment programs","volume":"115","author":"Jackson","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209086_bb0275","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2022.1776","article-title":"Methadone-involved overdose deaths in the US before and after federal policy changes expanding take-home methadone doses from opioid treatment programs","author":"Jones","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.josat.2023.209086_bb0280","author":"Joseph"},{"key":"10.1016\/j.josat.2023.209086_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108219","article-title":"Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19","volume":"122","author":"Joseph","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"7","key":"10.1016\/j.josat.2023.209086_bb0290","doi-asserted-by":"crossref","first-page":"e2118223","DOI":"10.1001\/jamanetworkopen.2021.18223","article-title":"Methadone access for opioid use disorder during the COVID-19 pandemic within the United States and Canada","volume":"4","author":"Joudrey","year":"2021","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/j.josat.2023.209086_bb0295","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/08897077.2021.1975344","article-title":"Research priorities for expanding access to methadone treatment for opioid use disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force report","volume":"42","author":"Joudrey","year":"2021","journal-title":"Substance Abuse"},{"key":"10.1016\/j.josat.2023.209086_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.107968","article-title":"Pharmacy-based methadone dispensing and drive time to methadone treatment in five states within the United States: A cross-sectional study","volume":"211","author":"Joudrey","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"13","key":"10.1016\/j.josat.2023.209086_bb0305","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1001\/jama.2019.12562","article-title":"Drive times to opioid treatment programs in urban and rural counties in 5 US states","volume":"322","author":"Joudrey","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.josat.2023.209086_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108258","article-title":"Considering the harms of our habits: The reflexive urine drug screen in opioid use disorder treatment","volume":"123","author":"Khatri","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209086_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugpo.2022.103644","article-title":"Impact of the COVID-19 pandemic on the provision of take-home doses of opioid agonist therapy in Ontario, Canada: A population-based time-series analysis","volume":"103","author":"Kitchen","year":"2022","journal-title":"The International Journal on Drug Policy"},{"issue":"1","key":"10.1016\/j.josat.2023.209086_bb0320","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1186\/s13643-021-01764-9","article-title":"Retention in opioid agonist treatment: A rapid review and meta-analysis comparing observational studies and randomized controlled trials","volume":"10","author":"Klimas","year":"2021","journal-title":"Systematic Reviews"},{"key":"10.1016\/j.josat.2023.209086_bb0325","author":"Knopf"},{"issue":"4","key":"10.1016\/j.josat.2023.209086_bb0330","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/YCO.0000000000000712","article-title":"The opioid overdose crisis as a global health challenge","volume":"34","author":"Krausz","year":"2021","journal-title":"Current Opinion in Psychiatry"},{"issue":"9","key":"10.1016\/j.josat.2023.209086_bb0335","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1001\/jamapsychiatry.2019.0876","article-title":"Buprenorphine treatment divide by race\/ethnicity and payment","volume":"76","author":"Lagisetty","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.josat.2023.209086_bb0340","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1080\/08897077.2021.1986768","article-title":"COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership","volume":"43","author":"Levander","year":"2022","journal-title":"Substance Abuse"},{"issue":"5","key":"10.1016\/j.josat.2023.209086_bb0345","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1111\/dar.13382","article-title":"Opioid agonist treatment and patient outcomes during the COVID-19 pandemic in south east Sydney, Australia","volume":"41","author":"Lintzeris","year":"2022","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.josat.2023.209086_bb0350","author":"Lintzeris"},{"key":"10.1016\/j.josat.2023.209086_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.109100","article-title":"Treatment provider perceptions of take-home methadone regulation before and during COVID-19","volume":"228","author":"Madden","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.josat.2023.209086_bb0360","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","volume":"2","author":"Mattick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1016\/j.josat.2023.209086_bb0365","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1377\/hlthaff.2018.05162","article-title":"Medication treatment for opioid use disorders in substance use treatment facilities","volume":"38","author":"Mojtabai","year":"2019","journal-title":"Health Affairs (Project Hope)"},{"key":"10.1016\/j.josat.2023.209086_bb0370","series-title":"Medications for opioid use disorder save lives","author":"National Academies of Sciences, E., and Medicine","year":"2019"},{"key":"10.1016\/j.josat.2023.209086_bb0375","article-title":"The estimated impact of state-level support for expanded delivery of substance use disorder treatment during the COVID-19 pandemic","author":"Nesoff","year":"2021","journal-title":"Addiction"},{"issue":"6","key":"10.1016\/j.josat.2023.209086_bb0380","doi-asserted-by":"crossref","first-page":"e2214765","DOI":"10.1001\/jamanetworkopen.2022.14765","article-title":"Racial and ethnic disparities in buprenorphine and extended-release naltrexone filled prescriptions during the COVID-19 pandemic","volume":"5","author":"Nguyen","year":"2022","journal-title":"JAMA Network Open"},{"issue":"3","key":"10.1016\/j.josat.2023.209086_bb0385","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/dar.12916","article-title":"What can Australia learn from the North American opioid crisis? The role of opioid regulation and other evidence-based responses","volume":"38","author":"Nielsen","year":"2019","journal-title":"Drug and Alcohol Review"},{"issue":"S1","key":"10.1016\/j.josat.2023.209086_bb0390","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1089\/pop.2020.0230","article-title":"The opioid epidemic within the COVID-19 pandemic: Drug testing in 2020","volume":"24","author":"Niles","year":"2021","journal-title":"Population Health Management"},{"key":"10.1016\/j.josat.2023.209086_bb0395","doi-asserted-by":"crossref","DOI":"10.1080\/00952990.2023.2222336","article-title":"Opioid use and COVID-19: A secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids","author":"Panwala","year":"2023","journal-title":"The American Journal of Drug & Alcohol Abuse"},{"issue":"6","key":"10.1016\/j.josat.2023.209086_bb0400","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/dar.12979","article-title":"The lived experience of Australian opioid replacement therapy recipients in a community-based program in regional Victoria","volume":"38","author":"Patil Vishwanath","year":"2019","journal-title":"Drug and Alcohol Review"},{"key":"10.1016\/j.josat.2023.209086_bb0405","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.drugpo.2019.01.020","article-title":"Comparing Canadian and United States opioid agonist therapy policies","volume":"74","author":"Priest","year":"2019","journal-title":"The International Journal on Drug Policy"},{"key":"10.1016\/j.josat.2023.209086_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.jsat.2020.108155","article-title":"Down the drain: Reconsidering routine urine drug testing during the COVID-19 pandemic","volume":"120","author":"Pytell","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.josat.2023.209086_bb0415","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12954-022-00671-z","article-title":"Opioid agonist treatment take-home doses (\u2018carries\u2019): Are current guidelines resulting in low treatment coverage among high-risk populations in Canada and the USA?","volume":"19","author":"Russell","year":"2022","journal-title":"Harm Reduction Journal"},{"key":"10.1016\/j.josat.2023.209086_bb0420","author":"SAMHSA"},{"key":"10.1016\/j.josat.2023.209086_bb0425","article-title":"\u201cThe idea is to help people achieve greater success and liberty\u201d: A qualitative study of expanded methadone take-home access in opioid use disorder treatment","author":"Suen","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.josat.2023.209086_bb0430","article-title":"Perspectives of opioid use disorder treatment providers during COVID-19: Adapting to flexibilities and sustaining reforms","volume":"132","author":"Treitler","year":"2021","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.josat.2023.209086_bb0435","author":"TurningPoint"},{"key":"10.1016\/j.josat.2023.209086_bb0440","series-title":"Victorian overdose deaths, 2011-2020","year":"2021"},{"issue":"1","key":"10.1016\/j.josat.2023.209086_bb0445","doi-asserted-by":"crossref","first-page":"E21","DOI":"10.1503\/cmaj.109-4054","article-title":"The redlining of harm reduction programs","volume":"184","author":"Webster","year":"2012","journal-title":"Cmaj"},{"issue":"10","key":"10.1016\/j.josat.2023.209086_bb0450","first-page":"377","article-title":"The potential use of telemedicine to increase access to opioid agonist therapy in rural and remote communities","volume":"62","author":"Weng","year":"2020","journal-title":"British Columbia Medical Journal"},{"issue":"1","key":"10.1016\/j.josat.2023.209086_bb0455","doi-asserted-by":"crossref","first-page":"45","DOI":"10.4103\/0976-3147.91934","article-title":"Buprenorphine vs methadone treatment: A review of evidence in both developed and developing worlds","volume":"3","author":"Whelan","year":"2012","journal-title":"Journal of Neurosciences in Rural Practice"}],"container-title":["Journal of Substance Use and Addiction Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923001376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949875923001376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T15:49:49Z","timestamp":1757432989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949875923001376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":79,"alternative-id":["S2949875923001376"],"URL":"https:\/\/doi.org\/10.1016\/j.josat.2023.209086","relation":{},"ISSN":["2949-8759"],"issn-type":[{"value":"2949-8759","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes to methadone maintenance therapy in the United States, Canada, and Australia during the COVID-19 pandemic: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Use and Addiction Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.josat.2023.209086","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"209086"}}